The Wolverine Stack Is Outside the Policy
The HHS enforcement discretion policy named BPC-157 and TB-500 — and simultaneously ruled out the most popular way they're sold.
The policy contains a condition most coverage skipped: each compounded product may contain only one active ingredient.
BPC-157 and TB-500 are frequently sold together in what's commonly called the "Wolverine stack" — a combination product marketed for recovery and healing. Under the HHS policy conditions, a premixed vial containing both falls outside the policy regardless of which peptides it contains.
Why This Matters
For patients: If a telehealth site or pharmacy is offering a combined BPC-157 and TB-500 product and claiming it's covered by the new policy, that claim is not accurate based on the policy's own text.
For clinics: Compliance with the policy requires dispensing each peptide as a separate product with a separate patient-specific prescription.
For the gray market: The single-ingredient condition, combined with requirements for FDA-registered API, patient-specific prescriptions, and certificates of analysis, means most of what is currently sold as "research use only" peptide blends falls entirely outside the policy's scope.
Other Conditions That Eliminate Common Products
The policy also requires that the only co-packaged delivery device be an FDA 510(k)-cleared syringe, so kits bundled with other mixing or reconstitution supplies do not qualify.
Oral formulations require documented human bioavailability evidence for the actual formulation. A tablet existing is not the same as having that documentation.
The Salt Matters
BPC-157 acetate is specifically named in the policy. BPC-157 arginate — a different salt of the same peptide — is not automatically covered. The salt designation is doing real regulatory work.
Similarly, N-Acetyl Semax Amidate is a different chemical compound from Semax free base. The policy covers Semax free base (intranasal only). N-Acetyl Semax Amidate is a different product and is not covered.
What the Policy Does Cover for BPC-157
Single-ingredient BPC-157 acetate (not arginate), dispensed by a licensed 503A pharmacy, on a patient-specific prescription from a licensed prescriber, with bulk substance from an FDA-registered, CGMP-compliant manufacturer and a valid certificate of analysis, in one of the allowed routes: subcutaneous, intramuscular, oral, or topical.
That is a meaningfully narrower set of conditions than most current marketing implies.
The Bottom Line
The policy opened a door for six peptides. It simultaneously closed the door on the way most of them are currently sold — in blends, without prescriptions, from unregistered suppliers.
A vendor claiming their combination peptide product is now "covered" or "legal" under the HHS policy is not accurately representing what the policy says.
Evidence limitation note: Policy conditions are paraphrased from the Federal Register notice (Doc. 2026-22192) and the Foley & Lardner and Frier Levitt analyses. What counts as one "active ingredient" in a specific product configuration is a legal question for qualified counsel. This is editorial analysis, not legal advice.
Sources
- Federal Register Doc. 2026-22192, published October 30, 2026.
- Docket HHS-OASH-2026-0496. regulations.gov
- Foley & Lardner, "Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides," October 30, 2026.
- Frier Levitt, "HHS Peptide Compounding Enforcement Discretion Policy," October 2026.
Published by PeptidesGPT, which offers a paid membership. PeptidesGPT is an educational platform; this post contains no product or purchase recommendations and does not constitute legal or medical advice. Consult a licensed healthcare provider for individualized medical guidance.
Keep reading with The Peptides Brief
One email a week on what the evidence actually says. No dosing, no hype.